{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:54:32Z","timestamp":1770987272900,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.vaccine.2018.07.078","type":"journal-article","created":{"date-parts":[[2018,8,4]],"date-time":"2018-08-04T21:50:26Z","timestamp":1533419426000},"page":"5766-5773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8735-6223","authenticated-orcid":false,"given":"Carlos","family":"Casta\u00f1eda-Orjuela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"De la Hoz-Restrepo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.07.078_b0005","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1473-3099(05)70083-9","article-title":"Epidemiological differences among pneumococcal serotypes","volume":"5","author":"Hausdorff","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.07.078_b0010","unstructured":"Pneumococcal conjugate vaccine for childhood immunization\u2013WHO position paper. Wkly Epidemiol Rec [Internet]. 2007 Mar 23 [cited 2015 Jul 29]; 82(12): 93\u2013104. <http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17380597>."},{"issue":"9693","key":"10.1016\/j.vaccine.2018.07.078_b0015","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","article-title":"Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates","volume":"374","author":"O\u2019Brien","year":"2009","journal-title":"Lancet [Internet]"},{"issue":"5","key":"10.1016\/j.vaccine.2018.07.078_b0020","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1590\/S1020-49892008001100002","article-title":"Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis","volume":"24","author":"Sinha","year":"2008","journal-title":"Rev Panam Salud Publica [Internet]."},{"issue":"3","key":"10.1016\/j.vaccine.2018.07.078_b0025","first-page":"270","article-title":"The burden of pneumococcal disease among Latin American and Caribbean children: review of the evidence","volume":"25","author":"Valenzuela","year":"2009","journal-title":"Pan Am J Public Heal"},{"issue":"11","key":"10.1016\/j.vaccine.2018.07.078_b0030","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.vaccine.2012.01.031","article-title":"Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children","volume":"30","author":"Casta\u00f1eda-Orjuela","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.078_b0035","unstructured":"Pan American Health Organization. Informe Regional de SIREVA II, 2010: Datos por pa\u00eds y por grupos de edad sobre las caracter\u00edsticas de los aislamientos de Haemophilus influenzae y Neisseria meningitidis en procesos invasores. Washington D.C.; 2011. p. 1\u2013306."},{"key":"10.1016\/j.vaccine.2018.07.078_b0040","unstructured":"Pan American Health Organization. Informe Regional de SIREVA II, 2011: Datos por pa\u00eds y por grupos de edad sobre las caracter\u00edsticas de los aislamientos de Haemophilus influenzae y Neisseria meningitidis en procesos invasores. Washington D.C.; 2012. p. 1\u2013306."},{"key":"10.1016\/j.vaccine.2018.07.078_b0045","unstructured":"Pan American Health Organization. Informe Regional de SIREVA II, 2012: Datos por pa\u00eds y por grupos de edad sobre las caracter\u00edsticas de los aislamientos de Haemophilus influenzae y Neisseria meningitidis en procesos invasores. Washington D.C.; 2013. p. 1\u2013306."},{"issue":"10","key":"10.1016\/j.vaccine.2018.07.078_b0050","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/14760584.2017.1362339","article-title":"Streptococcus pneumoniae serotype 19A: worldwide epidemiology","volume":"16","author":"Isturiz","year":"2017","journal-title":"Expert Rev Vaccines [Internet]"},{"issue":"40","key":"10.1016\/j.vaccine.2018.07.078_b0055","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1016\/j.vaccine.2012.03.054","article-title":"Population-based surveillance for invasive pneumococcal disease and pneumonia in infants and young children in Bogot\u00e1, Colombia","volume":"30","author":"Benavides","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2018.07.078_b0060","doi-asserted-by":"crossref","first-page":"315","DOI":"10.25100\/cm.v41i4.722","article-title":"Cost effectiveness of heptavalent pneumococcal conjugate vaccine in populations of high risk in Colombia","volume":"41","author":"Guzm\u00e1n","year":"2010","journal-title":"Colomb Med"},{"issue":"12","key":"10.1016\/j.vaccine.2018.07.078_b0065","first-page":"895","article-title":"Global estimate of the incidence of clinical pneumonia among children under five years of age","volume":"82","author":"Rudan","year":"2004","journal-title":"Bull World Health Organ [Internet]"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.078_b0070","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/infdis\/160.1.83","article-title":"Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study","volume":"160","author":"Teele","year":"1989","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.07.078_b0075","doi-asserted-by":"crossref","DOI":"10.1097\/00006454-200209000-00005","article-title":"Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia","volume":"21","author":"Black","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.07.078_b0080","doi-asserted-by":"crossref","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group","volume":"19","author":"Black","year":"2000","journal-title":"Pediatric Infect Disease J"},{"issue":"6","key":"10.1016\/j.vaccine.2018.07.078_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1001657","article-title":"Efficacy of pneumococcal nontypable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial","volume":"11","author":"Tregnaghi","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2018.07.078_b0090","unstructured":"Constenla D. The burden of pneumococcal disease and the cost effectiveness of a pneumococcal vaccine in Latin America and the Caribbean: a review of the evidence and a preliminary economic analysis [Internet]. Washington D.C.: The Albert B. Sabin Vaccine Institute, (SVI); Pan American Health Organization (PAHO); GAVI\u2019s Pneumococcal Accelerated Development and Introduction Plan at Johns Hopkins (PneumoADIP); Centers for Disease Control and Prevention (CDC); 2007 [cited 2015 Sep 24]. <http:\/\/www.ispch.cl\/sites\/default\/files\/document1.pdf>."},{"key":"10.1016\/j.vaccine.2018.07.078_b0095","unstructured":"World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis. Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans D, et al., editors. Geneva; 2003."},{"key":"10.1016\/j.vaccine.2018.07.078_b0100","series-title":"Methods for the economic evaluation of health care programmes","author":"Drummond","year":"2015"},{"key":"10.1016\/j.vaccine.2018.07.078_b0105","article-title":"Pneumococcal conjugate vaccine introduction in Latin America and the Caribbean: progress and lessons learned","volume":"1\u201310","author":"de Oliveira","year":"2016","journal-title":"Expert Rev Vaccines"},{"issue":"23","key":"10.1016\/j.vaccine.2018.07.078_b0110","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1016\/j.vaccine.2015.04.005","article-title":"Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada","volume":"33","author":"Deceuninck","year":"2015","journal-title":"Vaccine [Internet]"},{"issue":"49","key":"10.1016\/j.vaccine.2018.07.078_b0115","doi-asserted-by":"crossref","first-page":"9127","DOI":"10.1016\/j.vaccine.2011.09.112","article-title":"Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine","volume":"29","author":"Miller","year":"2011","journal-title":"Vaccine"},{"issue":"9512","key":"10.1016\/j.vaccine.2018.07.078_b0120","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0140-6736(06)68304-9","article-title":"Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study","volume":"367","author":"Prymula","year":"2006","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2018.07.078_b0125","doi-asserted-by":"crossref","first-page":"397","DOI":"10.15446\/rcciquifa.v44n3.56287","article-title":"Economic impact of vaccination with PCV13 vs. vaccination with PCV 10 in Colombia","volume":"44","author":"D\u00edaz","year":"2015","journal-title":"Rev Colomb Ciencias Qu\u00edmico \u2013 Farm [Internet]"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.078_b0130","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12962-015-0032-1","article-title":"Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia","volume":"13","author":"Ord\u00f3\u00f1ez","year":"2015","journal-title":"Cost Eff Resour Alloc [Internet]"},{"key":"10.1016\/j.vaccine.2018.07.078_b0135","unstructured":"Organizaci\u00f3n Panamericana de la Salud\/Organizaci\u00f3n Mundial de la Salud. Informe Regional de SIREVA II, 2014. Datos por pa\u00eds y por grupos de edad sobre las caracter\u00edsticas de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis, en procesos invasivos bacterianos [Internet]. Washington D.C.: OPS; 2017. p. 268. <http:\/\/iris.paho.org\/xmlui\/bitstream\/handle\/123456789\/33875\/9789275319420-spa.pdf?ua=1>."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18310983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18310983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T19:43:36Z","timestamp":1661715816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18310983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":27,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0264410X18310983"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.078","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}